Boissel N, Huguet F, Leguay T, Mathilde HB, Graux C, Chalandon Y, et al. In adults with Ph-negative acute lymphoblastic leukemia (ALL), age-adapted chemotherapy intensity and MRD-driven transplant indication significantly reduces treatment-related mortality (TRM) and improves overall survival - results from the Graall-2014 Trial. Blood. 2022;140:112–4. https://doi.org/10.1182/blood-2022-157903.

Article  Google Scholar 

Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, et al. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Lancet Haematol. 2022;9:e262–75. https://doi.org/10.1016/S2352-3026(22)00038-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, et al. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Adv. 2022;6:1115–25. https://doi.org/10.1182/bloodadvances.2021005624.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia. Blood. 2021;137:1879–94. https://doi.org/10.1182/blood.2020007311.

Article  CAS  PubMed  Google Scholar 

Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol. 2018;36:2514–23. https://doi.org/10.1200/JCO.2017.76.8192.

Article  CAS  PubMed  Google Scholar 

Goekbuget N, Baumann A, Beck J, Brueggemann M, Diedrich H, Huettmann A, et al. PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the german multicenter study group for adult ALL (GMALL) study 07/2003. Blood. 2010;116:494. https://doi.org/10.1182/blood.V116.21.494.494.

Article  Google Scholar 

Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023;7:4448–61. https://doi.org/10.1182/bloodadvances.2022009596.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lazzarotto D, Cerrano M, Papayannidis C, Chiaretti S, Mosna F, Fracchiolla N, et al. Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study. Haematologica. 2025;110:55–67. https://haematologica.org/article/view/haematol.2024.285638

CAS  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

Article  PubMed  PubMed Central  Google Scholar 

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4–10. https://doi.org/10.1016/j.bbmt.2015.09.001.

Article  PubMed  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21:389–401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001.

Article  PubMed  Google Scholar 

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:2113–23. https://doi.org/10.1016/j.bbmt.2019.08.014.

Article  PubMed  Google Scholar 

Giebel S, Labopin M, Socié G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139–49.

Article  PubMed  PubMed Central  Google Scholar 

Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486–96. https://doi.org/10.1182/blood-2014-09-599894.

Article  CAS  PubMed  Google Scholar 

Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–76. https://doi.org/10.1182/blood-2011-09-377713.

Article  CAS  PubMed  Google Scholar 

Pavlů J, Labopin M, Niittyvuopio R, Socié G, Yakoub-Agha I, Wu D, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12:108. https://doi.org/10.1186/s13045-019-0790-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31.

Article  PubMed  PubMed Central  Google Scholar 

Bassan R, Chiaretti S, Starza I, Della, Spinelli O, Santoro A, et al. Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab front-line trial for newly diagnosed adult PH-negative B-lineage ALL patients. EHA Libr. 2021;5:S114.

Google Scholar 

Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54:798–809. https://doi.org/10.1038/s41409-018-0373-4.

Article  PubMed  Google Scholar 

Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JH, Socié G, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023;58:874–80. https://doi.org/10.1038/s41409-023-01966-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, et al. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:997–1003. https://doi.org/10.1002/ajh.24823.

Article  CAS  PubMed  Google Scholar 

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, et al. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant [Internet]. 2018;24:726–33. https://doi.org/10.1016/j.bbmt.2017.11.025.

Article  CAS  PubMed  Google Scholar 

Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, et al. Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial. J Clin Oncol. 2022;41:343–53. https://doi.org/10.1200/JCO.22.00767.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2020;39:295–307. https://doi.org/10.1200/JCO.20.02529.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steiner N, Massoud R, Richter J, Perekhrestenko T, Gagelmann N, Niederwieser C, et al. Comparable results between 8 and 12 gray TBI in combination with fludarabine and post-transplant cyclophosphamide in MRD-negative but not in MRD-positive acute lymphoblastic leukemia patients transplanted in first complete remission. Eur J Haematol. 2025;114:79–88. https://doi.org/10.1111/ejh.14305.

Article  CAS  PubMed  Google Scholar 

Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035–44. https://doi.org/10.1016/S1470-2045(12)70349-2.

Article  PubMed